Logo image of BNGO

BIONANO GENOMICS INC (BNGO) Stock Fundamental Analysis

NASDAQ:BNGO - Nasdaq - US09075F3055 - Common Stock - Currency: USD

5.75  +0.61 (+11.87%)

After market: 5.47 -0.28 (-4.87%)

Fundamental Rating

2

Taking everything into account, BNGO scores 2 out of 10 in our fundamental rating. BNGO was compared to 57 industry peers in the Life Sciences Tools & Services industry. BNGO has a bad profitability rating. Also its financial health evaluation is rather negative. BNGO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BNGO had negative earnings in the past year.
BNGO had a negative operating cash flow in the past year.
In the past 5 years BNGO always reported negative net income.
In the past 5 years BNGO always reported negative operating cash flow.
BNGO Yearly Net Income VS EBIT VS OCF VS FCFBNGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -155.43%, BNGO is doing worse than 96.49% of the companies in the same industry.
BNGO's Return On Equity of -277.86% is on the low side compared to the rest of the industry. BNGO is outperformed by 89.47% of its industry peers.
Industry RankSector Rank
ROA -155.43%
ROE -277.86%
ROIC N/A
ROA(3y)-56.92%
ROA(5y)-67.49%
ROE(3y)-105.48%
ROE(5y)-252.38%
ROIC(3y)N/A
ROIC(5y)N/A
BNGO Yearly ROA, ROE, ROICBNGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BNGO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNGO Yearly Profit, Operating, Gross MarginsBNGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNGO has been increased compared to 1 year ago.
The number of shares outstanding for BNGO has been increased compared to 5 years ago.
The debt/assets ratio for BNGO is higher compared to a year ago.
BNGO Yearly Shares OutstandingBNGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
BNGO Yearly Total Debt VS Total AssetsBNGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.44, we must say that BNGO is in the distress zone and has some risk of bankruptcy.
BNGO's Altman-Z score of -5.44 is on the low side compared to the rest of the industry. BNGO is outperformed by 94.74% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that BNGO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.07, BNGO is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -5.44
ROIC/WACCN/A
WACC10.48%
BNGO Yearly LT Debt VS Equity VS FCFBNGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

BNGO has a Current Ratio of 1.43. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BNGO (1.43) is worse than 77.19% of its industry peers.
A Quick Ratio of 0.99 indicates that BNGO may have some problems paying its short term obligations.
BNGO's Quick ratio of 0.99 is on the low side compared to the rest of the industry. BNGO is outperformed by 82.46% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.99
BNGO Yearly Current Assets VS Current LiabilitesBNGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

BNGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.51%, which is quite impressive.
Looking at the last year, BNGO shows a decrease in Revenue. The Revenue has decreased by -0.85% in the last year.
Measured over the past years, BNGO shows a very strong growth in Revenue. The Revenue has been growing by 24.65% on average per year.
EPS 1Y (TTM)67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y61.97%
Revenue growth 5Y24.65%
Sales Q2Q%-34.83%

3.2 Future

BNGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.17% yearly.
The Revenue is expected to grow by 30.99% on average over the next years. This is a very strong growth
EPS Next Y64.63%
EPS Next 2Y38.49%
EPS Next 3Y24.56%
EPS Next 5Y15.17%
Revenue Next Year-19.65%
Revenue Next 2Y-7.64%
Revenue Next 3Y1.37%
Revenue Next 5Y30.99%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BNGO Yearly Revenue VS EstimatesBNGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
BNGO Yearly EPS VS EstimatesBNGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNGO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNGO Price Earnings VS Forward Price EarningsBNGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNGO Per share dataBNGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as BNGO's earnings are expected to grow with 24.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.49%
EPS Next 3Y24.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BNGO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONANO GENOMICS INC

NASDAQ:BNGO (1/30/2025, 5:49:16 PM)

After market: 5.47 -0.28 (-4.87%)

5.75

+0.61 (+11.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners11.76%
Inst Owner Change0.04%
Ins Owners0.09%
Ins Owner Change-0.07%
Market Cap586.44M
Analysts48.89
Price Target1.02 (-82.26%)
Short Float %17.34%
Short Ratio2.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.25%
Min EPS beat(2)-86.74%
Max EPS beat(2)48.24%
EPS beat(4)3
Avg EPS beat(4)9.48%
Min EPS beat(4)-86.74%
Max EPS beat(4)53.93%
EPS beat(8)3
Avg EPS beat(8)-0.45%
EPS beat(12)4
Avg EPS beat(12)-6.7%
EPS beat(16)6
Avg EPS beat(16)-7.43%
Revenue beat(2)0
Avg Revenue beat(2)-14.5%
Min Revenue beat(2)-24.19%
Max Revenue beat(2)-4.8%
Revenue beat(4)1
Avg Revenue beat(4)-7.12%
Min Revenue beat(4)-24.19%
Max Revenue beat(4)1.24%
Revenue beat(8)4
Avg Revenue beat(8)-3.25%
Revenue beat(12)7
Avg Revenue beat(12)-0.7%
Revenue beat(16)11
Avg Revenue beat(16)1.63%
PT rev (1m)0%
PT rev (3m)-47.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)61.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-45.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.59
P/FCF N/A
P/OCF N/A
P/B 12
P/tB 15.5
EV/EBITDA N/A
EPS(TTM)-1.54
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.33
BVpS0.48
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -155.43%
ROE -277.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.92%
ROA(5y)-67.49%
ROE(3y)-105.48%
ROE(5y)-252.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.47%
Cap/Sales 2.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 0.99
Altman-Z -5.44
F-Score2
WACC10.48%
ROIC/WACCN/A
Cap/Depr(3y)20.33%
Cap/Depr(5y)13.26%
Cap/Sales(3y)5.97%
Cap/Sales(5y)3.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y64.63%
EPS Next 2Y38.49%
EPS Next 3Y24.56%
EPS Next 5Y15.17%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y61.97%
Revenue growth 5Y24.65%
Sales Q2Q%-34.83%
Revenue Next Year-19.65%
Revenue Next 2Y-7.64%
Revenue Next 3Y1.37%
Revenue Next 5Y30.99%
EBIT growth 1Y39.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.67%
EBIT Next 3Y24.75%
EBIT Next 5YN/A
FCF growth 1Y21.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.46%
OCF growth 3YN/A
OCF growth 5YN/A